Share Name Share Symbol Market Type Share ISIN Share Description
Silence Therapeutics Plc LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 530.00 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
530.00 540.00 0.00 0.00 0.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -20.53 -26.20 414
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 0.00 GBX

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
11/12/201903:52Silence Therapeutics (the old SR Pharma)48,261
08/8/201905:43Lets Short This Duffer Out Of Business704
06/10/201608:04Gower Productions Presents ....."PREDICTA BID"52
29/5/201309:32Silence Therapeutics - news and views1,412

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-12-11 16:35:13530.005,63829,881.40UT
2019-12-11 16:30:08531.001,0005,310.00O
2019-12-11 16:28:50530.0075397.50AT
2019-12-11 16:28:35530.0044233.20AT
2019-12-11 16:28:31530.003481,844.40AT
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 530p.
Silence Therapeutics Plc has a 4 week average price of 380p and a 12 week average price of 165p.
The 1 year high share price is 610p while the 1 year low share price is currently 40p.
There are currently 78,094,027 shares in issue and the average daily traded volume is 81,901 shares. The market capitalisation of Silence Therapeutics Plc is £413,898,343.10.
learner9: This has a lot further to fall as current share price based on only wishful thinking
1gw: Incidentally, that LTIP shareprice "hurdle" looking rather out-of-date. Only announced on 7th October as well. It's amazing how far we've come. "The share price performance condition will be met if the average closing price of an Ordinary Share (or equivalent), whilst listed on a US stock exchange, exceeds £2.85 for all of the trading days in a 30-calendar-day period. " hTtps://
1gw: Another bullish interview with David Solomon on Proactive, talking about recent deals (MDCO, DRNA), discussions he's having about deals, timeline on SLN124 and safety expectations on RNAi drugs in general. Talks about 3-6+ months typically to finalise a deal but some of his discussions are already becoming advanced. With the share price where it is, and despite the intention to list in the US, it must be quite tempting to tap the UK market for some funds (i.e. placing) to give them perhaps the option of pursuing the Lp(a) target further by themselves - if only to strengthen their hand in negotiations around any deal for funding specific targets. Proactive interview can be found on the proactive investors site, dated yesterday and with the title "Silence Therapeutics CEO talks recent RNAi deals and updates on critical SLN124 trial".
martindkelly9: Mallinckrodt's share price is up 12% today (so far) and up 30% since 14 November. But even if they go bust, either (1) another pharma company will buy their rights to the deal with SLN (and so it will continue); or (2) or SLN keeps the $22m and is free to make a deal with another pharma company for the same drugs. So it is a win-win for SLN. Plus the external validation of SLN's platform is enduring and valuable.
horneblower: Certainly one of the drivers is the expectation of a US quote...strongly hinted at in the rns of 7th October. 1,814,500 options, equating to circa 70% of the total being awarded, only vest on the achievement of certain performance conditions within the vesting periods. These performance conditions include Silence achieving a listing on a US stock exchange and the subsequent achievement of a share price of GBP2.85, or the equivalent price in ADSs, if such an instrument has been issued. The share price performance condition will be met if the average closing price of an Ordinary Share (or equivalent), whilst listed on a US stock exchange, exceeds GBP2.85 for all of the trading days in a 30-calendar-day period. The Options are generally exercisable after vesting, until the 10(th) anniversary of the date of grant. Claw-back and malus provisions apply.
optimistic punter: I was in SLN way back before the share consolidation in 2013 and just noticed it back on my radar. Does anyone have any idea what the share price would have been in old money at current levels? Ie if they hadn't consolidated.Just trying to work out current value compared to when I sold out
lurker: Its a very silly precise number with a very silly reason behind it considering the share price has just hit serious resitance at £4...I bought just a few weeks ago and have already sold for a nice profit may not be a round number but at least it is real and in the here and now! I would say some unrealistic expectations here...eps are lower than in 2014 and share price is considerabley higher...
1gw: In terms of price action, who knows what drives the market? Doubtless the technicals played a part, but I also think there was probably some unease caused by the curious position of Malinckrodt - its own share price (and bond prices) cratering under heavy short selling and fears of it filing for chapter 11 bankruptcy protection due to opioid litigation and a dispute on drug pricing. What impact Ch 11 for MNK would have on Silence, I don't know, but perhaps it could impact the realisation of some of the milestone payments if it occurred at a bad time. I chose not to sell any this time round. There are a few potential near-term catalysts which could drive another spike and I didn't want to miss one if it happened. My hope is that we're following the ARWR path, a couple of years or so behind. I bought into ARWR, following the SLN purchase of ARWR shares, and sold out again after a decent rise (about a 40% average gain). But ARWR had a tremendous rise and those who held through the dips were very well rewarded - even after it has come off a bit recently, it is still around 10x higher than when I sold out. Potential near-term catalysts that I can see are: o Quark QP-1002 (DGF) outcome of negotiations with FDA on transition to New Drug Application process following completion of Phase III trials - expected this year (and possibly also Quark IPO which would invite valuation comparisons). o Announcement of licensing deal on LP(a) asset SLN360. Silence may fund the Phase 1 trial itself, but if it can get a good enough deal to license it then it may just do that instead. o Announcement of MNK exercising an option on another Complement asset. o Announcement of a licensing/collaboration deal on one of its extra-hepatic delivery assets/concepts. And of course, selling the company to big pharma (or another RNAi company) isn't entirely out of the question, although I suspect the company might think it would do better to get the share price up first by making progress on some of the above and perhaps taking SLN124 through at least Phase 1. One catalyst I thought might be coming up, a Silence IPO, sounds as though it's not on the near-term agenda, given David Solomon's comments on today's podcast.
1gw: Time for a bit of idle M&A speculation? In January 2017, when Ali parked the Silence tanks on Arrowhead's lawn ("potential corporate transaction" and "product licensing" mentioned in press release, among other things), he bought 9% of the company (ARWR) at an average of around $1.65/share. At the time Silence was around £1/share I think. Today ARWR is trading at around $28.85/share and Silence closed at £2.40. The xrate is about the same (Jan 2017 vs today) at £1=$1.25. So ARWR has gone up around 17.5 times, while SLN has done a bit better than doubled since the announcement of SLN's purchase of the ARWR position. In 2017, ARWR was so worried about the SLN move that it put in place a poison pill if I recall correctly. So, economic logic to one side for a minute, can you imagine the satisfaction in the ARWR C-suite if they could pick up SLN for a fraction of what they might have been looking at in terms of a corporate transaction back in 2017 (in terms of share exchange ratio), when they scrambled to put defences in place? But then look at the economic logic. At the recent R&D event we had SLN trumpeting it's LP(a) asset SLN360, which appears to be a potential competitor of the ARWR/Amgen AMG890 asset. So acquisition of SLN would remove the LP(a) competition threat, enabling ARWR to choose the best LP(a) asset - maybe even manage the transition from AMG890, which should be available first, to SLN360 which might be superior. Also it would remove the risk of any patent disputes with Silence, and ARWR would be in a position to take the best from each company's platforms. And perhaps best of all, ARWR might judge it would be positioned to capture a decent chunk of the upside from Silence asset success, if it thinks the SLN market value has the potential to follow ARWR's shareprice trajectory of the last couple of years as the SLN assets move into and through the clinic. You then look at the SLN shareholder base. Around 50% of the company (I estimate) held between Ali, Griffiths, Keith and Quested. So fairly easy to see who ARWR need to get onside if they want a deal to happen. It seems to me ARWR could quite easily justify a really juicy multiple of the current SLN share price to get SLN in an all-paper (or largely paper) transaction. Whether they could offer enough to convince Ali & co that it was an attractive alternative to going it alone, I don't know, but it seems to me it is a reasonable possibility. Post offered to try to provoke some reaction/discussion. Errors excepted, and no advice intended.
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191212 07:57:16